Overview

Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research is to learn acceptable dosages of paclitaxel, oxaliplatin, and Avastin (bevacizumab) that can be given in combination to patients with advanced peritoneal carcinomatosis. The safety of this drug combination will also be studied.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
Albumin-Bound Paclitaxel
Antibodies
Antibodies, Monoclonal
Bevacizumab
Oxaliplatin
Paclitaxel